Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma.
- 1 cites
A PGE2-COX-2 feedback loop in PMN-MDSCs suppresses T cell antitumor activity in KRAS-mutant cholangiocarcinoma, revealing a potential therapeutic target.
- Why it matters: Understanding how tumor metabolism impairs immune responses is crucial for improving immunotherapy effectiveness, especially in aggressive cancers with KRAS mutations.
- What they did: Multiomics analysis identified a subgroup with high COX/AA metabolism and KRAS mutations, revealing that KRAS-driven pathways recruit PMN-MDSCs and enhance PGE2 production, which suppresses T cells.
- The result: Targeting the COX-2-PGE2-EP4 axis alongside anti-PD-1 therapy significantly improves tumor control in models and patient samples, offering a promising treatment strategy.